Ultragenyx is reviewing program disposition and implementing significant expense reductions as brokerages cut price targets ...

Nate Hill, co-founder & CEO, Strive, notes the key milestone to watch for during the remaining step in FDA's formal Category ...

Recently, Pharmaceutical Executive spoke with Christian Thienel, director at Back Bay Life Sciences, about the ongoing issues ...

Pharmaceutical Executive recently spoke with Mark Cziraky, president of Carelon Research. The company just signed a deal with ...

Ultragenyx shares plunge after apazunersen fails its Phase III trial in Angelman syndrome, Mark Cziraky of Carelon Research ...

Melanie Whittington, managing director and head of the Leerink Center for Pharmacoeconomics, joins Ron Lanton to argue that ...

Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...

Nate Hill, Co-Founder & CEO of Strive Pharmacy, describes how the company approaches uncertainty around peptide inventory, ...

Structural margin compression is driving companies to seek operational savings that can be reinvested into portfolio development and late-stage de-risking. AI adoption is widespread for ...

Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer ...

Eli Lilly & Company and Merida Biosciences announced a definitive agreement for Eli Lilly to acquire Merida, to advance ...

The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA ...